Literature DB >> 16909327

Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients.

Omer Karadag1, Meral Calguneri, Enver Atalar, Bunyamin Yavuz, Ali Akdogan, Umut Kalyoncu, Sule Apras Bilgen, Necla Ozer, A Ihsan Ertenli, Kenan Ovunc, Sedat Kiraz.   

Abstract

Systemic lupus erythematosus (SLE) is associated with severe and premature cardiovascular disease, which cannot be explained by traditional risk factors alone. This study aims to investigate novel cardiovascular risk factors and cardiac event predictors in inactive SLE female patients who do not have any major cardiovascular risk factors. Twenty-five inactive (SLE disease activity index score <4) SLE female patients and 22 healthy control women were studied. SLE patients with a history of diabetes mellitus, hypertension, hyperlipidemia, smoking, or coronary artery disease (CAD) were excluded. Venous blood samples were analyzed for lipid subfractions and novel cardiovascular risk factors such as lipoprotein (a), homocysteine, fibrinogen, high-sensitivity C-reactive protein (hs-CRP), and serum amyloid A (SAA) levels. Endothelial dysfunction was assessed by flow-mediated dilatation (FMD) from the brachial artery at baseline and during reactive hyperemia. SLE patients and controls were similar in terms of age (40+/-10 years vs 38+/-10 years, p = NS). No significant difference was found between the groups regarding family history of premature CAD, blood pressure, body mass index, lipoprotein (a), homocysteine, fibrinogen, SAA, apoprotein A-1 and B levels. Compared with the controls, SLE patients had higher levels of hs-CRP [median (range): 1.82 (0.02-0.98) vs 0.68 (0.02-0.35), p=0.04]. FMD was lower in SLE patients than controls (7.1+/-2.1 vs 11.4+/-1.2%, p<0.001). Increased levels of hs-CRP and decreased FMD were found in inactive SLE patients. Increased hs-CRP levels may reflect ongoing low-grade inflammation that could be a cause of impaired FMD in SLE patients. These findings suggest that SLE patients without traditional major cardiovascular risk factors may have increased risk of cardiovascular disease and future cardiac events.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16909327     DOI: 10.1007/s10067-006-0376-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  20 in total

1.  Systemic lupus erythematosus and accelerated atherosclerosis.

Authors:  Bevra Hannahs Hahn
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

2.  Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study.

Authors:  S Manzi; E N Meilahn; J E Rairie; C G Conte; T A Medsger; L Jansen-McWilliams; R B D'Agostino; L H Kuller
Journal:  Am J Epidemiol       Date:  1997-03-01       Impact factor: 4.897

3.  Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease.

Authors:  B Takase; A Uehata; T Akima; T Nagai; T Nishioka; A Hamabe; K Satomura; F Ohsuzu; A Kurita
Journal:  Am J Cardiol       Date:  1998-12-15       Impact factor: 2.778

4.  Brachial endothelial function is impaired in patients with systemic lupus erythematosus.

Authors:  Domingos S N Lima; Emilia I Sato; Valter C Lima; Fausto Miranda; Francisca H Hatta
Journal:  J Rheumatol       Date:  2002-02       Impact factor: 4.666

5.  Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus.

Authors:  M Petri; R Roubenoff; G E Dallal; M R Nadeau; J Selhub; I H Rosenberg
Journal:  Lancet       Date:  1996-10-26       Impact factor: 79.321

6.  The bimodal mortality pattern of systemic lupus erythematosus.

Authors:  M B Urowitz; A A Bookman; B E Koehler; D A Gordon; H A Smythe; M A Ogryzlo
Journal:  Am J Med       Date:  1976-02       Impact factor: 4.965

7.  Fibrinogen in systemic lupus erythematosus: more than an acute phase reactant?

Authors:  P R Ames; J Alves; A F Pap; P Ramos; M A Khamashta; G R Hughes
Journal:  J Rheumatol       Date:  2000-05       Impact factor: 4.666

8.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

Review 9.  Atherosclerosis and systemic lupus erythematosus.

Authors:  Mohammed Abusamieh; Julia Ash
Journal:  Cardiol Rev       Date:  2004 Sep-Oct       Impact factor: 2.644

10.  Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study.

Authors:  Ian N Bruce; Murray B Urowitz; Dafna D Gladman; Dominique Ibañez; George Steiner
Journal:  Arthritis Rheum       Date:  2003-11
View more
  10 in total

1.  Brain Atrophy, Anti-Smooth Muscle Antibody and Cognitive Impairment: An Association Study.

Authors:  Paroni Giulia; Lauriola Michele; Fontana Andrea; D'Onofrio Grazia; Ciccone Filomena; Paris Francesco; Cascavilla Leandro; Urbano Maria; Gravina Carolina; Copetti Massimiliano; Greco Antonio
Journal:  Aging Dis       Date:  2015-11-24       Impact factor: 6.745

2.  Decreased flow-mediated dilatation in patients with systemic lupus erythematosus: a meta-analysis.

Authors:  De-Guang Wang; Xiao-Wu Tang; Ye Fan; Rui-Xue Leng; Jing Ni; Sen-Miao Deng; Chao Wang; Han Cen; Hai-Feng Pan; Dong-Qing Ye
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

3.  The correlation between the cardio-ankle vascular index (CAVI) and serum amyloid A in asymptomatic Japanese subjects.

Authors:  Kazuhiko Kotani; Toshiyuki Yamada; Michiaki Miyamoto; Kazuomi Kario; Shun Ishibashi; Nobuyuki Taniguchi
Journal:  Heart Vessels       Date:  2011-09-03       Impact factor: 2.037

4.  Heterogeneity of peripheral blood monocytes, endothelial dysfunction and subclinical atherosclerosis in patients with systemic lupus erythematosus.

Authors:  T P Mikołajczyk; G Osmenda; B Batko; G Wilk; M Krezelok; D Skiba; T Sliwa; J R Pryjma; T J Guzik
Journal:  Lupus       Date:  2015-08-06       Impact factor: 2.911

5.  Therapeutic options for premature coronary artery disease.

Authors:  Ameen F Person; Cam Patterson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-08

6.  High-sensitivity C-reactive protein, disease activity, and cardiovascular risk factors in systemic lupus erythematosus.

Authors:  Chi Chiu Mok; Daniel J Birmingham; Ling Yin Ho; Lee A Hebert; Brad H Rovin
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-03       Impact factor: 4.794

Review 7.  Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases).

Authors:  Elisa Gremese; Barbara Tolusso; Maria Rita Gigante; Gianfranco Ferraccioli
Journal:  Front Immunol       Date:  2014-11-11       Impact factor: 7.561

8.  Endothelial dysfunction in systemic lupus erythematosus - a case-control study and an updated meta-analysis and meta-regression.

Authors:  Anselm Mak; Nien Yee Kow; Herbert Schwarz; Lingli Gong; Sen Hee Tay; Lieng Hsi Ling
Journal:  Sci Rep       Date:  2017-08-04       Impact factor: 4.379

9.  Association between serum total antioxidant status and flow-mediated dilation in patients with systemic lupus erythematosus: an observational study.

Authors:  İsa Sincer; Ertuğrul Kurtoğlu; Fatma Yılmaz Çoşkun; Semra Aktürk; Ertan Vuruşkan; İrfan Veysel Düzen; Erhan Saraçoğlu; Erdal Aktürk; Şıho Hidayet
Journal:  Anatol J Cardiol       Date:  2015-03-05       Impact factor: 1.596

Review 10.  Cardiovascular involvement in autoimmune diseases.

Authors:  Jenny Amaya-Amaya; Laura Montoya-Sánchez; Adriana Rojas-Villarraga
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.